The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the recommendations by international medical associations including EULAR and the ACR, is mostly eminence-based rather than evidence-based. However, knowledge on SLE is growing quickly, and such new advances need to be translated into clinical practice. Questions remain regarding the choice and timing of drug administration and tapering until withdrawal, which both can affect the balance between the control of disease activity and damage to organs triggered by long-standing and/or disproportionate immunosuppression. Currently, the treating physicians of patients with SLE are required to weigh the present with the future situation of their patients in an optimized balance between therapeutic harm and benefit. In this Review, the available therapeutic strategies and main challenges in the approach to SLE treatment are discussed. Remission and low disease activity are desirable therapeutic goals. Although the drug armamentarium for SLE has not expanded much in the past few decades, there are nonetheless opportunities to make better choices and explore combination therapies; such opportunities offer the potential of a personalized medicine strategy.
Early diagnosis and early treatment are required for a better outcome in systemic lupus erythematosus (SLE).
Preventive strategies should be applied at any stage of the disease course to minimize disease evolution or worsening; potential comorbidities should be prevented from the start of SLE treatment.
The achievement of clinical remission and subsequent tapering of glucocorticoids until withdrawal are desirable subsequent steps in SLE management.
Even when remission cannot be attained, the treatment of patients with SLE should be optimized to achieve the lowest stable level of disease activity.
Tapering of treatment should be initiated once there is a stable response and requires careful monitoring.
Patient-tailored therapeutic strategies should consider the immunological background, clinical features, realistic potential for recovery and the expectations of each patient.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Rheumatology and Therapy Open Access 31 March 2022
Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis
Journal of Translational Medicine Open Access 19 January 2021
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Doria, A. et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am. J. Med. 119, 700–706 (2006).
Jorge, A. M., Lu, N., Zhang, Y., Rai, S. K. & Choi, H. K. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999–2014). Rheumatology (Oxford) 57, 337–344 (2018).
Yen, E. Y. & Singh, R. R. Lupus-an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000–2015. Arthritis. Rheumatol. 70, 1251–1255 (2018).
Van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73, 958–967 (2014).
Little, J. et al. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford) 57, 677–687 (2018).
Wallace, D. J. et al. Systemic lupus erythematosus-survival patterns. Experience with 609 patients. JAMA 245, 934–938 (1981).
Doria, A. et al. SLE diagnosis and treatment: when early is early. Autoimmun. Rev. 10, 55–60 (2010).
Nightingale, A. L., Davidson, J. E., Molta, C. T., Kan, H. J. & McHugh, N. J. Presentation of SLE in UK primary care using the Clinical Practice Research Datalink. Lupus. Sci. Med. 4, e000172 (2017).
Oglesby, A. et al. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl. Health. Econ. Health. Policy. 12, 179–190 (2014).
Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526–1533 (2003).
Rees, F. et al. Early clinical features in systemic lupus erythematosus: can they be used to achieve earlier diagnosis? A risk prediction model. Arthritis Care Res. (Hoboken) 69, 833–841 (2017).
Arriens, C., Wren, J. D., Munroe, M. E. & Mohan, C. Systemic lupus erythematosus biomarkers: the challenging quest. Rheumatology (Oxford) 56, i32–i45 (2017).
Compagno, M. et al. Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study. Scand. J. Rheumatol. 42, 311–316 (2013).
Piga, M. et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis. Res. Ther. 19, 247 (2017).
Nossent, J. et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19, 949–956 (2010).
Iaccarino, L. et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J. Autoimmun. 86, 1–8 (2018). This paper presents the first large, prospective, multicentre study on the real-life use of belimumab in SLE and its clinical effects.
Esdaile, J. M., Joseph, L., MacKenzie, T., Kashgarian, M. & Hayslett, J. P. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J. Rheumatol. 21, 2046–2051 (1994).
Jacobsen, S. et al. Prognostic value of renal biopsy and clinical variables in patients with lupus nephritis and normal serum creatinine. Scand. J. Rheumatol. 28, 288–299 (1999).
Faurschou, M., Starklint, H., Halberg, P. & Jacobsen, S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J. Rheumatol. 33, 1563–1569 (2006).
Ciruelo, E., De la Cruz, J., López, I. & Gómez-Reino, J. J. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis. Rheum. 39, 2028–2034 (1996).
Fiehn, C. et al. Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann. Rheum. Dis. 62, 435–439 (2003).
Munroe, M. E. et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014–2021 (2016). This paper highlights the occurrence of immunological abnormalities in the very early stages of SLE development and sheds new light on pathogenesis.
Lu, R. et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J. Autoimmun. 74, 182–193 (2016).
Calixto, O. J., Franco, J. S. & Anaya, J. M. Lupus mimickers. Autoimmun. Rev. 13, 865–872 (2014).
Doria, A. & Briani, C. Primary prevention of systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 4, 576–577 (2008).
Doria, A. & Briani, C. Lupus: improving long-term prognosis. Lupus 17, (166–170 (2008).
Munroe, M. E. et al. Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features. Arthritis Rheumatol. 69, 630–642 (2017). This paper explores the topic of anticipating the onset of systemic autoimmunity in SLE, which might shift the border of prevention and treatment.
Durcan, L. & Petri, M. Immunomodulators in SLE: clinical evidence and immunologic actions. J. Autoimmun. 74, 73–84 (2016).
Bizzarro, N. et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J. Thromb. Haemost. 5, 1158–1164 (2007).
Pengo, V. et al. Efficacy and safety of rivaroxaban versus warfarin in high-risk patients with antiphospholipid syndrome: rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 25, 301–306 (2016).
Arnaud, L. et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun. Rev. 14, 192–200 (2015).
Ruiz-Irastorza, G. et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus 20, 206–218 (2011).
Erkan, D. et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 56, 2382–2391 (2007).
Moroni, G. et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol. Dial. Transplant. 22, 2531–2539 (2007).
Lateef, A. & Petri, M. Unmet medical needs in systemic lupus erythematosus. Arthritis. Res. Ther. 14 (Suppl. 4), S4 (2012).
Doria, A. et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann. Rheum. Dis. 73, 154–160 (2014).
Moroni, G. et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann. Rheum. Dis. 77, 1318–1325 (2018). This study explores the changes in patterns of demographic, clinical and histological presentation in lupus nephritis over five decades, the longest observational period of its kind.
Golder, V. et al. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis. Res. Ther. 18, 260 (2016).
van Vollenhoven, R. et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann. Rheum. Dis. 76, 554–561 (2017).
Zen, M. et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann. Rheum. Dis. 74, 2117–2122 (2015).
Polachek, A., Gladman, D. D., Su, J. & Urowitz, M. B. Defining low disease activity in systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 69, 997–1003 (2017).
Franklyn, K. et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann. Rheum. Dis. 75, 1615–1621 (2016). This paper is the first to propose a definition of LDA in SLE.
Ugarte-Gil, M. F. et al. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). Ann. Rheum. Dis. 76, 2071–2074 (2017).
Zen, M. et al. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. Ann. Rheum. Dis. 75, 562–565 (2017). This paper is the first to identify a clear period of remission that is associated with protection from organ damage.
Zen, M. et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann. Rheum. Dis. 77, 104–110 (2018).
Mok, C. C. et al. Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. Ann. Rheum. Dis. 76, 1420–1425 (2017).
Tsang-A-Sjoe, M. W. et al. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford) 56, 121–128 (2017).
Petri, M. & Magder, L. S. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol. 70, 1790–1795 (2018).
Formiga, F. et al. High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus. Rheumatology (Oxford) 38, 724–727 (1999).
Medina-Quiñones, C. V., Ramos-Merino, L., Ruiz-Sada, P. & Isenberg, D. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res. (Hoboken) 68, 981–987 (2016).
Urowitz, M. B., Feletar, M., Bruce, I. N., Ibañez, D. & Gladman, D. D. Prolonged remission in systemic lupus erythematosus. J. Rheumatol. 32, 1467–1472 (2005).
Drenkard, C., Villa, A. R., Garcia-Padilla, C., Pérez-Vázquez, M. E. & Alarcón-Segovia, D. Remission of systematic lupus erythematosus. Medicine (Baltimore) 75, 88–98 (1996).
Isenberg, D. A. et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann. Rheum. Dis. 70, 54–59 (2011).
Aranow, C. A pilot study to determine the optimal timing of the Physician Global Assessment (PGA) in patients with systemic lupus erythematosus. Immunol. Res. 63, 167–169 (2015).
Bertsias, G. et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann. Rheum. Dis. 71, 1771–1782 (2012).
Chen, Y. E., Korbet, S. M., Katz, R. S., Schwartz, M. M. & Lewis, E. J. Value of a complete or partial remission in severe lupus nephritis. Clin. J. Am. Soc. Nephrol. 3, 46–53 (2008).
Houssiau, F. A. et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis. Rheum. 50, 3934–3940 (2004).
Medina-Rosas, J., Yap, K. S., Anderson, M., Su, J. & Touma, Z. Utility of urinary protein-creatinine ratio and protein content in a 24-hour urine collection in systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 68, 1310–1319 (2016).
Houssiau, F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 46, 2121–2131 (2002).
Dall’Era, M. et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 67, 1305–1313 (2015).
Tamirou, F. et al. MAINTAIN nephritis trial investigators. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN nephritis trial. Lupus. Sci. Med. 12, e000123 (2015).
Arriens, C. et al. Prognostic significance of repeat biopsy in lupus nephritis: histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin. Immunol. 185, 3–9 (2017).
Moroni, G., Depetri, F. & Ponticelli, C. Lupus nephritis: when and how often to biopsy and what does it mean? J. Autoimmun. 74, 27–40 (2016).
Touma, Z. et al. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J. Rheumatol. 41, 688–697 (2014).
Moroni, G. et al. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin. Arthritis Rheum. 41, 642–651 (2012).
Moroni, G. et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol. Dial. Transplant. 21, 1541–1548 (2006).
Mosca, M., Tani, C. & Aringer, M. Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal? Clin. Exp. Rheumatol. 31 (Suppl. 78), S71–S74 (2013).
Gordon, C. et al. British Society for Rheumatology standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatolohy (Oxford) 57, e1–e45 (2018).
Bertsias, G. K. et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann. Rheum. Dis. 69, 2074–2082 (2010).
Pons-Estel, B. A. et al. Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann. Rheum. Dis. 77, 1549–1557 (2018).
Posnick, J. Systemic lupus erythematosus. The effect of corticotropin and adrenocorticoid therapy on survival rate. Calif. Med. 98, 308–312 (1963).
Merrill, J. T. et al. The biomarkers of lupus disease study: a bold approach may mitigate interference of background immunosuppressants in clinical trials. Arthritis Rheumatol. 69, 1257–1266 (2017). This study explores the consequences of immunosuppression-free regimens in SLE and indirectly shows the insufficient effects of corticosteroids in maintaining long-term treatment responses.
Bruce, I. N. et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann. Rheum. Dis. 74, 1706–1713 (2015).
Al Sawah, S. et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus. Sci. Med. 2, e000066 (2015).
Guiducci, C. et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937–941 (2010).
Edwards, J. C., Snaith, M. L. & Isenberg, D. A. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualized outcome assessment. Ann. Rheum. Dis. 46, 773–776 (1987).
Fischer-Betz, R. et al. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study. J. Rheumatol. 39, 2111–2117 (2012).
Ruiz-Irastorza, G. et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun. Rev. 16, 826–832 (2017).
Zeher, M. et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus 20, 1484–1493 (2011).
Merrill, J. T. et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus. Sci. Med. 5, e000258 (2018).
Lightstone, L. et al. Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmun. Rev. 17, 4–10 (2018). This commentary provides a complete overview of the evidence supporting or cautioning against steroid-free regimens in lupus nephritis.
Condon, M. B. et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72, 1280–1286 (2013).
Porter, A. B. et al. Long term follow up of the Rituxilup steroid sparing regimen in lupus nephritis [abstract FR-OR065]. J. Am. Soc. Nephrol. 25, 61A (2014).
Pepper, R. et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol. Dial. Transplant. 24, 3717–3723 (2009).
Pillay, C., Levy, J. B., Cairns, T. & Lightstone, L. G. M. Treating lupus nephritis with rituximab and mycophenolate mofetil (rituxirescue regimen) without increasing maintenance oral steroids leads to sustained disease remission and steroid reduction. J. Am. Soc. Nephrol. 27, 500A (2016).
Iaccarino, L. et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. (Hoboken) 69, 115–123 (2017).
Ginzler, E. M. et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J. Rheumatol. 41, 300–309 (2014).
Trentin, F. et al. Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE: a review of observational clinical-practice-based studies. Clin. Rev. Allergy Immunol. 54, 331–343 (2018).
Bruce, I. N. et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus 25, 699–709 (2016).
Liu, Z. et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann. Intern. Med. 162, 18–26 (2015).
Zhang, H. et al. Multitarget therapy for maintenance treatment of lupus nephritis. J. Am. Soc. Nephrol. 28, 3671–3678 (2017).
Furie, R. et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376–386 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03021499?term=NCT03021499&rank=1 (2018).
Watanabe, H. et al. The efficacy of add-on tacrolimus for minor flare in patients with systemic lupus erythematosus: a retrospective study. Lupus 25, 54–60 (2016).
Mok, C. C. Calcineurin inhibitors in systemic lupus erythematosus. Best Pract. Res. Clin. Rheumatol. 31, 429–438 (2017).
Gracia-Tello, B. et al. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. Lupus. Sci. Med. 4, e000182 (2017).
Roccatello, D. et al. Intensive short term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy. Nephrol. Dial. Transplant. 26, 3987–3989 (2011).
Ruiz-Arruza, I. et al. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high disease activity at diagnosis. Autoimmun. Rev. 14, 875–879 (2015). This study shows that low-dose steroids are as effective as high-dose steroids during induction treatment and have a better safety profile.
Gladman, D. D., Iban˜ez, D., Ruiz, I. & Urowitz, M. B. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. J. Rheumatol. 40, 630–633 (2013).
Bertsias, G. et al. Task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann. Rheum. Dis. 67, 195–205 (2008).
Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. & Khamashta, M. A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69, 20–28 (2010).
Hsu, C. Y. et al. Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus. Rheumatology (Oxford) 57, 1743–1751 (2018).
Alarcón, G. S. et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann. Rheum. Dis. 66, 1168–1172 (2007).
Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis. Rheum. 54, 3284–3290 (2006).
Costedoat-Chalumeau, N. et al. Routine hydroxychloroquine blood concentration measurement in systemic lupus erythematosus reaches adulthood. J. Rheumatol. 42, 1997–1999 (2015).
Ting, T. V. et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J. Rheumatol. 39, 174–179 (2012).
Costedoat-Chalumeau, N. et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin. Pharmacol. Ther. 103, 1074–1082 (2018).
Durcan, L., Clarke, W. A., Magder, L. S. & Petri, M. Hydroxychloroquine blood levels in systemic lupus erythematosus: clarifying dosing controversies and improving adherence. J. Rheumatol. 42, 2092–2097 (2015).
Fessler, B. J. et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum. 52, 1473–1480 (2005).
Pons-Estel, G. et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 61, 830–839 (2009).
Londoño Jimenez, A. et al. Tubulointerstitial damage in lupus nephritis: a comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheumatol. 70, 1801–1806 (2018).
Pego-Reigosa, J. M. et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res. (Hoboken) 65, 1775–1785 (2013).
Allison, A. C. & Eugui, E. M. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin. Transplant. 10, 77–84 (1996).
Chen, W. et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial. Lupus 21, 944–952 (2012).
Dooley, M. A. et al. Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract]. Arthritis Rheumatol. 68 (Suppl. 10), 5L (2016).
Fu, J. et al. Transcriptomic analysis uncovers novel synergistic mechanisms in combination therapy for lupus nephritis. Kidney. Int. 93, 416–429 (2018). The researchers of this study, in a transcriptomic analysis, shed light on the synergistic effects of combination therapy.
Kraaij, T. et al. TAC-TIC use of tacrolimus-based regimens in lupus nephritis. Lupus Sci. Med. 3, e000169 (2016).
van Vollenhoven, R. et al. Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomized placebo-controlled study [abstract]. Arthritis. Rheumatol. 69 (Suppl. 10), 6L (2017).
Wallace, D. J. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392, 222–231 (2018).
Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918–3930 (2011).
Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721–731 (2011).
Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222–233 (2010).
Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 64, 1215–1226 (2012).
Iaccarino, L. et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. Clin. Exp. Rheumatol. 33, 449–456 (2015).
McCarthy, E. M. et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles lupus assessment group biologics register. Rheumatology (Oxford) 57, 470–479 (2018).
Witt, M. et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 22, 1142–1149 (2013).
Hahn, B. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. (Hoboken) 64, 797–808 (2012).
Jovancevic, B., Lindholm, C. & Pullerits, R. Anti B cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus 22, 664–674 (2013).
Hofmann, S. C., Leandro, M. J., Morris, S. D. & Isenberg, D. A. Effects of rituximab-based B cell depletion therapy on skin manifestations of lupus erythematosus—report of 17 cases and review of the literature. Lupus 22, 932–939 (2013).
Weidenbusch, M., Römmele, C., Schröttle, A. & Anders, H. J. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol. Dial. Transplant. 28, 106–111 (2013).
Ezeonyeji, A. N. & Isenberg, D. A. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology (Oxford) 51, 476–481 (2012).
Stohl, W. et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 69, 1016–1027 (2017).
Fanouriakis, A. et al. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: a real-life observational study. Semin. Arthritis Rheum. https://doi.org/10.1016/j.semarthrit.2018.02.014 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01639339?term=NCT01639339&rank=1 (2018).
Dooley, M. A. et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22, 63–72 (2013).
Kraaij, T., Huizinga, T. W., Rabelink, T. J. & Teng, Y. K. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford) 53, 2122–2124 (2014).
Simonetta, F., Allali, D., Roux-Lombard, P. & Chizzolini, C. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine 84, 235–236 (2017).
Psarelis, S., Nikiphorou, E. & Boumpas, D. T. Successful use of sequential B cell depletion therapy in lupus. Lupus 27, 345–346 (2018).
Carter, L. M., Isenberg, D. A. & Ehrenstein, M. R. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65, 2672–2679 (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03312907?term=NCT03312907&rank=1 (2018).
Specchia, M. L. et al. Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus. Biomed. Res. Int. 2014, 704207 (2014).
Vallejo-Aparicio, L. A., Díaz-Cerezo, S., Parrondo, J. & García-Aparicio, A. M. Cost-effectiveness analysis of belimumab in the treatment of adult systemic lupus erythematosus (Sle) Patients With Positive Biomarkers In Spain. Value. Health. 17, A530 (2014).
Athanasakis, K. et al. Belimumab for the treatment of systemic lupus erythematosus (Sle) in Greece: a cost-effectiveness and cost-utility analysis. Value Health 17, A532–A533 (2014).
National Institute for Health and Care Excellence. Final appraisal determination: belimumab for treating active autoantibody-positive systemic lupus erythematosus. NICE https://www.nice.org.uk/guidance/ta397/documents/final-appraisal-determination-document (2016).
European Medicines Agency. Benlysta: EPAR- product information. Annex I: summary of product characteristics. ema.europa https://www.ema.europa.eu/documents/product-information/benlysta-epar-product-information_en.pdf (2017).
van Vollenhoven, R. F. et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann. Rheum. Dis. 71, 1343–1349 (2012).
Dooley, M. A. et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N. Engl. J. Med. 365, 1886–1895 (2011).
Houssiau, F. A. et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann. Rheum. Dis. 69, 2083–2089 (2010).
Zen, M. et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin. Exp. Rheumatol. 30, 856–863 (2012).
Györi, N. et al. Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. Lupus. Sci. Med. 4, e000192 (2017).
Bakker, M. F., Jacobs, J. W., Verstappen, S. M. & Bijlsma, J. W. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann. Rheum. Dis. 66 (Suppl. 3), 56–60 (2007).
Aljohani, R., Gladman, D. D., Su, J. & Urowitz, M. B. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clin. Rheumatol. 36, 1773–1778 (2017).
Steiman, A. J. et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res. 64, 511–518 (2012).
Zahr, Z. A., Fang, H., Magder, L. S. & Petri, M. Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort. Lupus 22, 697–701 (2013).
Mosca, M., Tani, C., Carli, L. & Bombardieri, S. Glucocorticoids in systemic lupus erythematosus. Clin. Exp. Rheumatol. 29 (Suppl. 68), S126–S129 (2011).
The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 324, 150–482 (1991).
Levy, R. et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo controlled study. Lupus 10, 401–404 (2001).
Tsakonas, E. et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 7, 80–85 (1998).
Costedoat-Chalumeau, N. et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann. Rheum. Dis. 72, 1786–1792 (2013).
Mok, C. C. et al. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res. (Hoboken) 68, 1295–1302 (2016).
Cunha, C. et al. Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol. Dial. Transplant. 33, 1604–1610 (2017).
Ugarte, A., Danza, A. & Ruiz-Irastorza, G. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. Curr. Opin. Rheumatol. 30, 482–489 (2018).
Sharon, E., Kaplan, D. & Diamond, H. S. Exacerbation of systemic lupus erythematosus after withdrawal of azathioprine therapy. N. Engl. J. Med. 288, 122–124 (1973).
Nikpour, M., Urowitz, M., Ibanez, D. & Gladman, D. D. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 61, 1152–1158 (2009).
Pablos, J. L., Gutierrez-Millet, V. & Gomez-Reino, J. J. Remission of lupus nephritis with cyclophosphamide and late relapses following therapy withdrawal. Scand. J. Rheumatol. 23, 142–144 (1994).
Mosca, M. et al. Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis. Lupus 10, 253–225 (2001).
Moroni, G., Longhi, S., Gliglio, E., Messa, P. & Ponticelli, C. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin. Exp. Rheumatol. 31, S75–S81 (2013).
Barturen, G. & Alarcón-Riquelme, M. E. Systemic lupus erythematosus in 2016: gene expression profiling comes closer to the clinic. Nat. Rev. Rheumatol. 13, 69–70 (2017).
Pirone, C. et al. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): a systematic review. Semin. Arthritis Rheum. 47, 384–396 (2017).
Dall’Era, M., Stone, D., Levesque, V., Cisternas, M. & Wofsy, D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res. (Hoboken) 63, 351–357 (2011).
Gottenberg, J. E. et al. Efficacy of epratuzumab, an anti-CD22 monoclonal IgG antibody, in systemic lupus erythematosus patients with associated sjögren’s syndrome: post Hoc analyses from the EMBODY trials. Arthritis Rheumatol. 70, 763–773 (2018).
Teruel, M., Chamberlain, C. & Alarcón-Riquelme, M. E. Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases. Rheumatology (Oxford) 56, i78–i87 (2017).
Barturen, G. & Alarcón-Riquelme, M. E. SLE redefined on the basis of molecular pathways. Best Pract. Res. Clin. Rheumatol. 31, 291–305 (2017).
Toro-Domínguez, D. et al. Longitudinal stratification of gene expression reveals three SLE groups of disease activity progression. Arthritis Rheumatol. https://doi.org/10.1002/art.40653 (2018).
Coit, P. et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+T cells from lupus patients. J. Autoimmun. 43, 78–84 (2013).
Jeffries, M. A. et al. Genome-wide DNA methylation patterns in CD4+T cells from patients with systemic lupus erythematosus. Epigenetics 6, 593–601 (2011).
Chiche, L. et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol. 66, 1583–1595 (2014).
Li, Y. & Wu, T. Proteomic approaches for novel systemic lupus erythematosus (SLE) drug discovery. Exp. Opin. Drug. Discov. 13, 765–777 (2018).
Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711–723 (2003).
Ghodke-Puranik, Y. & Niewold, T. B. Immunogenetics of systemic lupus erythematosus: a comprehensive review. J. Autoimmun. 64, 125e136 (2015).
Zhan, Y., Guo, Y. & Lu, Q. Aberrant epigenetic regulation in the pathogenesis of systemic lupus erythematosus and its implication in precision medicine. Cytogenet. Genome Res. 149, 141–155 (2016).
Coit, P. et al. Epigenome profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils. J. Autoimmun. 58, 59–66 (2015).
Tang, Y. et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 60, 1065–1075 (2009).
Coit, P. et al. Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+T cells. J. Autoimmun. 61, 29–35 (2015).
Yang, Y. et al. The effect of mycophenolic acid on epigenetic modifications in lupus CD4+T cells. Clin. Immunol. 158, 67–76 (2015).
Chafin, C. B., Regna, N. L., Hammond, S. E. & Reilly, C. M. Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. Int. Immunopharmacol. 17, 894–906 (2013).
Reilly, C. M. et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun. 31, 123–130 (2008).
Barturen, G., Beretta, L., Cervera, R., Van Vollenhoven, R. & Alarcón-Riquelme, M. E. Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nat. Rev. Rheumatol. 14, 180 (2018).
Flint, S. M. et al. Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases. RMD Open 2, e000183 (2016).
Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551–565 (2016). This article presents the first longitudinal study to monitor the transcriptomic profile of patients with SLE and uncover genetic signatures linked to disease manifestations and therapeutic responses in SLE.
Peterson, K. S. et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J. Clin. Invest. 113, 1722–1733 (2004).
Stratigou, V. et al. Altered expression of signalling lymphocyte activation molecule receptors in T cells from lupus nephritis patients-a potential biomarker of disease activity. Rheumatology (Oxford) 56, 1206–1216 (2017).
Enghard, P. et al. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann. Rheum. Dis. 73, 277–283 (2014).
Jourde-Chiche, N. et al. Modular transcriptional repertoire analyses identify a blood neutrophil signature as a candidate biomarker for lupus nephritis. Rheumatology (Oxford) 56, 477–487 (2017).
Wither, J. E. et al. Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: clinical/pathologic associations and etiologic mechanisms. PLOS ONE 13, e0196117 (2018).
Khamashta, M. et al. CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 75, 1909–1916 (2016).
Isenberg, D. et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus(SLE): 52-week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74, 2006–2015 (2015).
Ginzler, E. M. et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther. 14, R33 (2012).
Gordon, C. et al. Post Hoc analysis of the phase II/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. Arthritis Rheumatol. 69, 122–130 (2017).
Magder, L. S. & Petri, M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am. J. Epidemiol. 176, 708–719 (2012).
van Assen, S. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 70, 414–422 (2011).
Andreoli, L. et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 76, 476–485 (2017).
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of an-tiretroviral agents in HIV-1-infected adults and adolescents. tdm-torino http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (2011).
Freifeld, A. G. et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin. Infect. Dis. 52, e56 (2011).
Dreyer, L. et al. High incidence of potentially virus-induced malignancies in systemic lupus eryhematosus. Arthritis Rheum. 63, 3032–3037 (2011).
Bernatsky, S. R. et al. Cancer screening in patients with systemic lupus erythematosus. J. Rheumatol. 33, 45–49 (2006).
Watts, N. B. et al. American Association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr. Pract. 16 (Suppl. 3), 1–37 https://www.aace.com/publications/guidelines (2010).
Grossman, J. M. et al. American College of Rheumatology 2010. Recommendations for the prevention and treatment of gluco-corticoid induced osteoporosis. Arthritis Care Res. (Hoboken) 62, 1515–1526 (2010).
Iaccarino, L. et al. Overlap connective tissue disease syndromes. Autoimmun. Rev. 12, 363–373 (2013).
Tektonidou, M. G. Antiphospholipid syndrome nephropathy: from pathogenesis to treatment. Front. Immunol. 9, 1181 (2018).
Sève, P. et al. Lupus-like presentation of parvovirus B19 infection. Semin. Arthritis Rheum. 34, 642–648 (2005).
Verdolini, R. et al. Systemic lupus erythematosus induced by Epstein–Barr virus infection. Br. J. Dermatol. 146, 877–881 (2002).
Bezanahary, H. et al. Systemic lupus erythematosus and herpes virus infection: three new observations. Rev. Med. Interne. 23, 1018–1021 (2002).
Saravana, S., James, D. W., Abourawi, F., Gupta, P. C. & Samyukta, B. HIV infection mimicking SLE. Clin. Rheumatol. 23, 562–563 (2004).
Khosravi, A. R. et al. Severe tinea corporis due to Trichophyton verrucosum mimicking discoid lupus erythematosus. J. Mycol. Med. 22, 92–95 (2012).
Arlet, J. B., Capron, L. & Pouchot, J. Visceral leishmaniasis mimicking systemic lupus erythematosus. J. Clin. Rheumatol. 16, 203–204 (2010).
Hammoudeh, M. Acute lymphocytic leukemia presenting as lupus-like syndrome. Rheumatol. Int. 26, 581–582 (2006).
Yilmaz, M. et al. Histiocytic necrotizing lymphadenitis (Kikuchi–Fujimoto’s disease) mimicking systemic lupus erythematosus: a review of two cases. Lupus 15, 384–387 (2006).
Suwannaroj, S., Elkins, S. L. & McMurray, R. W. Systemic lupus erythematosus and Castleman’s disease. J. Rheumatol. 26, 1400–1403 (1999).
Diaz, J. C., Vallejo, S. & Cañas, C. Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab. Rheumatol. Int. 32, 3315–3317 (2012).
Soldevilla, H. F., Briones, S. F. R. & Navarra, S. V. Systemic lupus erythematosus following HPV immunization or infection? Lupus 21, 158–161 (2012).
The authors thank T. Manning for help with revising the English language of the manuscript.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gatto, M., Zen, M., Iaccarino, L. et al. New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 15, 30–48 (2019). https://doi.org/10.1038/s41584-018-0133-2
This article is cited by
Nature Reviews Rheumatology (2022)
Stem Cell Reviews and Reports (2022)
A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus
Rheumatology and Therapy (2022)
Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis
Journal of Translational Medicine (2021)
Nature Immunology (2020)